Business Of Biotech
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
- Update frequency
- every 7 days
- Average duration
- 49 minutes
- Episodes
- 270
- Years Active
- 2020 - 2025
Drug Delivery Differentiators with Syncromune's Eamonn Hobbs
We love to hear from our listeners. Send us a message.
Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a …
Topical Ocular Biologics with Claris Bio's Clarke Atwell
We love to hear from our listeners. Send us a message.
Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology …
C&G Regulatory Guidance with Lineage Therapeutics' Brian Culley
We love to hear from our listeners. Send us a message.
When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving …
True DEI Value in Biopharma with Arcellx's Rami Elghandour
We love to hear from our listeners. Send us a message.
The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong pe…
Mission-Driven Dementia Funding with DDF's Jonathan Behr
We love to hear from our listeners. Send us a message.
If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-ven…
ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller
We love to hear from our listeners. Send us a message.
Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. Bu…
Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D.
We love to hear from our listeners. Send us a message.
Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted tra…
The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch
We love to hear from our listeners. Send us a message.
This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's n…
A New Prescription For PBMs with Allan Shaw
We love to hear from our listeners. Send us a message.
Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharma…
New Apps For AI in mRNA With Anima Biotech's Yochi Slonim
We love to hear from our listeners. Send us a message.
From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global te…
Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch
We love to hear from our listeners. Send us a message.
As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editor…
Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D.
We love to hear from our listeners. Send us a message.
Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective i…
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.
We love to hear from our listeners. Send us a message.
This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to…
Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, D.Phil.
We love to hear from our listeners. Send us a message.
Ampersand Biomedicines CEO Jason Gardner, D.Phil. first took the leap from a global pharmaceutical giant to a startup at the forefront of transp…
Funding Alzheimer's Tx Dev with ADDF's Karen Harris
We love to hear from our listeners. Send us a message.
We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at t…
The AI Impact with Generate:Biomedicines' Mike Nally
We love to hear from our listeners. Send us a message.
Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artif…
Strategic Deals with CinRx's Gavin Samuels, M.D.
We love to hear from our listeners. Send us a message.
Gavin Samuels, M.D. found his work as an intensive care physician boring. After earning his M.D., he did that for a few years before moving into…
Serial Success With Triumvira's Rob Williamson
We love to hear from our listeners. Send us a message.
Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acqu…
The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D.
We love to hear from our listeners. Send us a message.
In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is prai…
Precision Radiopharmaceuticals with Ratio's Jack Hoppin, Ph.D.
We love to hear from our listeners. Send us a message.
Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put o…